Vir Biotechnology Past Earnings Performance
Past criteria checks 0/6
Vir Biotechnology has been growing earnings at an average annual rate of 6%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 34.6% per year.
Key information
6.0%
Earnings growth rate
42.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 34.6% |
| Return on equity | -34.9% |
| Net Margin | -677.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05
Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Oct 12Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B
Oct 04Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus
Sep 22Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs
Aug 09Vir: Biotechnology's Best Near-Term Capital Gain Prospect
Jul 27Vir Biotechnology announces transition of chief scientific officer
Jul 14Revenue & Expenses BreakdownBeta
How Vir Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 80 | -539 | 164 | 5 |
| 31 Dec 23 | 86 | -615 | 174 | 63 |
| 30 Sep 23 | 119 | -601 | 174 | 50 |
| 30 Jun 23 | 491 | -262 | 176 | 197 |
| 31 Mar 23 | 446 | -144 | 170 | 197 |
| 31 Dec 22 | 1,616 | 516 | 162 | 53 |
| 30 Sep 22 | 2,379 | 1,143 | 139 | 280 |
| 30 Jun 22 | 2,108 | 1,078 | 147 | 0 |
| 31 Mar 22 | 2,326 | 1,216 | 134 | 0 |
| 31 Dec 21 | 1,095 | 529 | 161 | 43 |
| 30 Sep 21 | 284 | -102 | 128 | 0 |
| 30 Jun 21 | 183 | -297 | 96 | 0 |
| 31 Mar 21 | 73 | -390 | 84 | 0 |
| 31 Dec 20 | 76 | -299 | 71 | 0 |
| 30 Sep 20 | 76 | -257 | 60 | 0 |
| 30 Jun 20 | 75 | -220 | 50 | 0 |
| 31 Mar 20 | 10 | -223 | 42 | 0 |
| 31 Dec 19 | 8 | -175 | 38 | 0 |
| 30 Sep 19 | 10 | -137 | 33 | 0 |
| 30 Jun 19 | 12 | -122 | 31 | 0 |
| 31 Mar 19 | 12 | -117 | 30 | 0 |
| 31 Dec 18 | 11 | -116 | 29 | 0 |
| 31 Dec 17 | 3 | -70 | 22 | 0 |
Quality Earnings: VIR is currently unprofitable.
Growing Profit Margin: VIR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIR is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare VIR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: VIR has a negative Return on Equity (-34.86%), as it is currently unprofitable.